Medial Inguino-Femoral Lymphadenectomy for Vulvar Cancer: An Approach to Decrease Lymphedema without Compromising Survival.
inguino-femoral lymphadenectomy
lateral inguinal nodes
lymphedema
medial inguinal nodes
vulvar cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
19 Nov 2021
19 Nov 2021
Historique:
received:
25
08
2021
revised:
19
10
2021
accepted:
16
11
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
11
2021
Statut:
epublish
Résumé
Lower limb lymphedema is a long-term complication of inguino-femoral lymphadenectomy and is related to the number of lymph nodes removed. Our hypothesis was that lymph nodes lateral to the femoral artery could be left in situ if the medial nodes were negative, thereby decreasing this risk. We included patients with vulvar cancer of any histological type, even if the cancer extended medially to involve the urethra, anus, or vagina. We excluded patients whose tumor extended (i) laterally onto the thigh, (ii) posteriorly onto the buttocks, or (iii) anteriorly onto the mons pubis. After resection, the inguinal nodes were divided into a medial and a lateral group, based on the lateral border of the femoral artery. Between December 2010 and July 2018, 76 patients underwent some form of groin node dissection, and data were obtained from 112 groins. Approximately one-third of nodes were located lateral to the femoral artery. Positive groin nodes were found in 29 patients (38.2%). All patients with positive nodes had positive nodes medial to the femoral artery. Five patients (6.6%) had positive lateral inguinal nodes. The probability of having a positive lateral node given a negative medial node was estimated to be 0.00002. Provided the medial nodes are negative, medial inguino-femoral lymphadenectomy may suffice and should reduce lower limb lymphedema without compromising survival.
Sections du résumé
BACKGROUND
BACKGROUND
Lower limb lymphedema is a long-term complication of inguino-femoral lymphadenectomy and is related to the number of lymph nodes removed. Our hypothesis was that lymph nodes lateral to the femoral artery could be left in situ if the medial nodes were negative, thereby decreasing this risk.
METHODS
METHODS
We included patients with vulvar cancer of any histological type, even if the cancer extended medially to involve the urethra, anus, or vagina. We excluded patients whose tumor extended (i) laterally onto the thigh, (ii) posteriorly onto the buttocks, or (iii) anteriorly onto the mons pubis. After resection, the inguinal nodes were divided into a medial and a lateral group, based on the lateral border of the femoral artery.
RESULTS
RESULTS
Between December 2010 and July 2018, 76 patients underwent some form of groin node dissection, and data were obtained from 112 groins. Approximately one-third of nodes were located lateral to the femoral artery. Positive groin nodes were found in 29 patients (38.2%). All patients with positive nodes had positive nodes medial to the femoral artery. Five patients (6.6%) had positive lateral inguinal nodes. The probability of having a positive lateral node given a negative medial node was estimated to be 0.00002.
CONCLUSION
CONCLUSIONS
Provided the medial nodes are negative, medial inguino-femoral lymphadenectomy may suffice and should reduce lower limb lymphedema without compromising survival.
Identifiants
pubmed: 34830958
pii: cancers13225806
doi: 10.3390/cancers13225806
pmc: PMC8616189
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Am J Obstet Gynecol. 1975 Oct 15;123(4):349-55
pubmed: 1166863
Gynecol Oncol. 1983 Feb;15(1):65-77
pubmed: 6822368
Eur Urol. 2008 Oct;54(4):885-90
pubmed: 18502024
Radiol Bras. 2019 Sep-Oct;52(5):316-324
pubmed: 31656350
Radiology. 2020 Jan;294(1):223-229
pubmed: 31746690
Int J Radiat Oncol Biol Phys. 1992;24(2):389-96
pubmed: 1526880
J Nucl Med. 2018 Jul 20;:
pubmed: 30030346
Gynecol Oncol. 2010 Mar;116(3):473-7
pubmed: 19922986
Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):151-165
pubmed: 27271051
Ultrasound Obstet Gynecol. 2020 Mar;55(3):401-410
pubmed: 31237047
Gynecol Oncol. 2016 Jan;140(1):8-14
pubmed: 26428940
Int J Gynecol Cancer. 2007 Jan-Feb;17(1):147-53
pubmed: 17291246
Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):2064-71
pubmed: 26219869
Am J Obstet Gynecol. 1974 Jan 15;118(2):159-62
pubmed: 4809402
Int J Gynecol Cancer. 2020 Mar;30(3):383-386
pubmed: 32075896
J Clin Oncol. 2008 Feb 20;26(6):884-9
pubmed: 18281661
Surg Gynecol Obstet. 1948 Dec;87(6):679-94
pubmed: 18120502
Int J Gynecol Cancer. 2007 Jan-Feb;17(1):154-8
pubmed: 17291247
Gynecol Oncol. 2014 Jun;133(3):416-20
pubmed: 24631445
Int J Radiat Oncol Biol Phys. 1993 Nov 15;27(4):969-74
pubmed: 8244831
Br J Cancer. 2014 Jun 10;110(12):2837-46
pubmed: 24867697
Gynecol Oncol. 2008 Nov;111(2):282-8
pubmed: 18804850
BJOG. 2018 Oct;125(11):1461-1468
pubmed: 29924914
Gynecol Oncol. 2015 Dec;139(3):458-64
pubmed: 26432039
Am J Obstet Gynecol. 1979 Apr 1;133(7):825-32
pubmed: 434024
Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3303-3314
pubmed: 33619601
Am J Obstet Gynecol. 1991 Apr;164(4):997-1003; discussion 1003-4
pubmed: 2014852
Obstet Gynecol. 1992 Apr;79(4):490-7
pubmed: 1553164